NG11-2 Phase-Ib Clinical Study Results Summary Available

A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer

3rd -March- 2025 –

VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, is pleased to announce that the full clinical trial report has been completed. A summary of the NG11-2-P1b clinical study results is now publicly released on the VasoDynamics website here. NG11-2 is an oral topical prescription drug to reduce and prevent severe Radiation-Induced Oral Mucositis (RIOM). Further details will also be available on public domains such as ISRCTN registry and clinical trials.gov website .

Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:

“From the readout of the Phase-Ib trial, NG11-2 oral topical solution is well tolerated and shows positive signals to enable the decision of progressing into a pivotal trial. We are delighted to release the existing results of the NG11-2 Phase 1b study, and we welcome further funding and partnerships to support moving the NG11-2 product into a larger scale pivotal trial and market approval.”

For enquiries, please contact:

Dr Ningfeng Fiona Li, CEO
fiona.li@vasodynamics.co.uk

Gary Bower, COO
gary.bower@vasodynamics.co.uk

Notes to Editors:

About VasoDynamics

VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy induced mucositis, dermatitis, and hair-loss. We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a serials of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during various types of cancer treatments.